→ MAZZUCCO

A61K 31/19

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07C 59/84, 229/26, 279/14, C07D 295/08, A61K 31/19 | A1

(11) International Publication Number: WO 94/20449

(43) International Publication Date: 15 September 1994 (15.09.94)

(21) International Application Number: PCT/IT94/00020

(22) International Filing Date: 7 March 1994 (07.03.94)

(30) Priority Data:
MI93A000447 9 March 1993 (09.03.93) IT
MI94A000348 25 February 1994 (25.02.94) IT

(71) Applicants (*for all designated States except US*): DOMPE' FARMACEUTICI SPA [IT/IT]; Via San Martino, 12-12/a, I-20122 Milano (IT). DOMPE' SPA [IT/IT]; Via Campo di Pile, I-67100 L'Aquila (IT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BOSONE, Enrico [IT/IT]; Via Washington, 80, I-20146 Milano (IT). CLAVENNA, Gaetano [IT/IT]; Via Tommaso Grossi, 29, I-20017 Rho (IT). GANDOLFI, Carmelo [IT/IT]; Via M.A. Colonna, 9, I-20149 Milano (IT). MANTOVANINI, Marco [IT/IT]; Via Gran San Bernardo, 6, I-20145 Milano (IT). CURTI, Roberto [IT/IT]; Via Giordano Orsini, 8, I-20147 Milano (IT).

(74) Agent: BENEDUCE, Gianna; Via Poggibonsi, 7, I-20146 Milano (IT).

Ketoprofen

(81) Designated States: AU, BB, BG, BR, CA, CN, CZ, FI, HU, JP, KP, KR, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: SALTS OF 2-(3-BENZOYLPHENYL)PROPIONIC ACID WITH ACHIRAL AND CHIRAL ORGANIC BASES AND PHARMACEUTICAL COMPOSITIONS THEREOF

(57) Abstract

The salts of S(+) 2-(3-benzoylphenyl)propionic acid and of R(-) 2-(3-benzoylphenyl)propionic acid with an achiral, organic base such as tris-(hydroxymethyl)aminomethane or a chiral organic base such as D-lysine, L-lysine, L-arginine, (R) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol and (S) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol, the process for their preparation and the corresponding pharmaceutical compositions containing said salts are described.

Tromethamine

Dexpirizi

10:23:37

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo			SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

Description

Salts of 2-(3-benzoylphenyl)propionic acid with achiral and chiral organic bases and pharmaceutical compositions thereof

Technical Field

The object of the present invention relates to salts of 2-(3-benzoylphenyl)propionic acid with achiral and chiral organic bases, and to the pharmaceutical compositions containing them.

A further object of the invention relates to the process for the preparation of said salts.

More particularly, the present invention relates to the salts of the S(+) and R(-) enantiomers of 2-(3-benzoylphenyl)propionic acid with achiral amine, such as, for example, tris-(hydroxymethyl)aminomethane, also known as tromethamine, and with chiral amine such as, for example (R) and (S) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol, also known as dextrodropropizine and levodropropizine, and with basic α-aminoacids such as, for example, D-lysine, L-lysine and L-arginine, all salts which may be separated as single chemical individuals of high optical purity.

Background of the Invention

Because of its high tolerability, the (S,R) (±) 2-(3-benzoylphenyl)propionic acid, also known as ketoprofen, is one of the non-steroidal anti-inflammatories of widespread use in clinics, both for the treatment of serious inflammatory conditions and for its use as an anagelsic and antipyretic. Pharmaceutical compositions of current use containing

ketoprofen, have racemate as its active principle, where the two enantiomers S(+) and R(-) are present in equimolecular ratio between themselves.

The active principle is normally used as free acid, practically insoluble in water, in pharmaceutical compositions destined for oral use, while for alternative ways of administration, for example that of parenteral administration, adaptable ketoprofen salts with organic and inorganic bases are used.

In the past, all the pharmacological activities peculiar to the racemate of 2-arylpropionic chiral acid, were thought to be constitutive of the enantiomer S(+) which only was found to inhibit the endogenous synthesis of the pro-inflammatory algogene and pirogene prostaglandines, in which respect the antipode R(-) is inactive or practically so. On the other hand, it is well known that the R(-) enantiomer of the 2-arylpropionic acids undergoes, to a variable extent and in a way animal species dependent, metabolic epimerization in the S(+) enantiomer, an event which, for a long time, has prevented a correct characterization of the pharmacological properties of the individual enantiomers.

Only recently, using flurbiprofen, a chiral 2-arylpropionic anti-inflammatory and analgesic acid, whose enantiomers are not metabolically converted one into another, K. Brune et al. (Exprientia, 47, 257, 1991) have clearly shown that the inhibition of the prostaglandine synthesis mainly mediates the anti-inflammatory activity of the compound, while mechanisms independent from the inhibition of the prostaglandine synthesis contribute to the analgesic effects of the racemate. Of the two antipodes, the S(+) form inhibits the

prostaglandine synthesis, the inflammation and the perception of the pain, while the R(-) antipode, which has much less effect on the inhibition of the prostaglandine synthesis and has no effect on the inflammation, blocks the perception of the pain with a potency rather similar to that of the antipode S(+).

S(+) flubiprofen is clearly ulcerogenic for the gastroenteric mucose, unlike the R(-) enantiomer. On the basis of these results, the A.A.s conclude on the existence of additional mechanisms of analgesia and propose a new and correct therapeutic use of the R(-) 2-arilpropionic acids as analgesics.

These concepts are further enphatized in a successive article (K. Brune et al., J. Clin, Pharmacol., 32, 944, 1992) where it is concluded that, having recourse to the use of individual enantiomers of the chiral 2-arilpropionic acids instead of the racemate, it is possible:

a) to reduce the dose and by that the metabolic load;

b) to reduce the variability in clinical response by eliminating the biochemical inversion pathway;

c) to reduce compliance problems due to unnecessarily high doses;

d) to establish more specific drug treatment (R-enantiomers in occasional pain, S-enantiomers in rheumatic disorders).

Description of the invention

The object of the present invention relates to pharmacologically active salts of 2-(3-benzoylphenyl)-propionic acid with achiral and chiral organic bases and to the process of their preparation and to the pharmaceutical

compositions containig them.

More particularly those are salts of the enantiomeric forms S(+) and R(-) of the 2-(3-benzoylphenyl)propionic acid with achiral amines such as, for example, tris(hydroxymethyl)aminomethane, also known as tromethamine, and with chiral amines such as, for example, (R) and (S) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol, also known as dextrodropropizine and levodropropizine, and with basic α-aminoacids such as, for example, D-lysine, L-lysine and L-arginine, salts which may all be isolated as single chemical individuals having high optical purity.

The salts of S(+) 2-(3-benzoylphenyl)propionic acid with the above-mentioned bases are in particular usefully employed in the treatment of those pathological symptoms of rheumatoid and cronic type, which require the drug to be administered at high dosage, continuously and for long periods of time.

In such event, the presence in the racemic form of the enantiomer R(-), which is ineffective as an inflammatory drug, would represent for the patient an unnecessary metabolic load which would even be harmful. In fact the optical antipode R(-), which is pharmacologically inactive in inhibiting the prostaglandine synthesis, and therefore as anti-inflammatory agent, does not or only very slightly and in a kinetically and therapeutically inefficient way, undergo epimerization in man to the enantiomeric form S(+) to which the anti-inflammatory activity of the racemate are due.

The salts of the R(-) 2-(3-benzoylphenyl)propionic acid with the above-mentioned bases are in particular usefully employed in treating acute painful symptoms of spastic type (renal, biliary or hepatic colics) and/or tissue-type characterized by

sensibilization of the nerve ends and/or of traumatic type. More generally and in some situations of acute pain, the same compounds could be proposed as a true alternative to the use of narcotics.

It is important and desirable that for the treatment of acute and very painful manisfestations, there are pharmaceutical compositions suitable for immediate use and manageable, which rapidly release the active principle and are of high bio-availability.

Typical examples of these compositions are those by parenteral administration and/or by oral administration which are drinkable, which allow a fine dispersion of the active principle. Due to the scarce solubility in water of the active principle, it is necessary to resort, for these purposes, to the use of salts, as single chemical individuals or obtained by extemporary salification during the pharmaceutical formulation process.

Pharmaceutical formulations are known which contain salts of racemic ketoprofen and those containing sodium salt (ketoalgine^{R}) and D,L-lysine salts (Artrosilene^{R}) are of current use.

More recently, in patent applications WO 93/16689 (2802, 1992) and WO 93/17677 (09.03.1992) relating to the use of R(-) ketoprofen as an analgesic, pharmaceutical compositions containing as active principle R(-) ketoprofen or a salt thereof with pharmaceutically acceptable organic and inorganic non-toxic bases, are indicated. In both cases, a general reference is made to addition salts of R(-) ketoprofen with various metal ions among which those with alkaline and earth-alkaline metals and with various organic bases, among

which the salts with the basic amino acids, such as lysine and arginine.

While the salification process of a chiral 2-arylpropionic acid, in the racemic form, does not involve problems concerning the chemical racemizations of the active principle, this aspect assumes a noticeable relevance when the salification involves the same chemical species but in their optically active form.

In the latter case, the possibility of an oncoming chemical racemization during the salification, drying and storage processes of the raw material, or successively in a state of solution, or during manipulation of the pharmaceutical formulation, cannot be excluded.

It follows that the salification process, the characteristic of the chemical specie salt, the more appropriate to preserve the integrity of the active principle, are not accessory elements of the manipulation and of the practical utilization of the enantiomerically pure active principle.

The salts of the R(-) 2-(3-benzoylphenyl)propionic acid or R(-) ketoprofen, the salts of the S(+) 2-(3-benzoylphenyl)propionic acid or S(+) ketoprofen with achiral organic bases, such as for example, tromethamine, or with chiral, enantiomerically pure, organic bases, such as L-lysine, D-lysine, L-arginine, (S) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol and (R) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol have been obtained as single chemical individuals, and form the object of present invention.

The process for preparing the above said salts consists of a salification reaction, in a suitable solvent and kept warm, of

one of the above-mentioned bases, with R(-) 2-(3-benzouylphenyl)propionic acid or S(+) 2-(3-benzoylphenyl)propionic acid, having an enantiomeric purity of no less than 95%. After cooling, the corresponding salts separate themselves in a good yield, as such or after re-crystallization, and contain the salifying acid which has an optical purity of no less than 99%.

Preferred solvents used in the salification reaction are alcohols such as methanol, ethanol, propanol and isopropanol; ketones such as acetone; water and /or mixtures containing such solvents.

In the salification process with one of the above mentioned α-aminoacids, specifically in the case of lysine, the solvent more particularly preferred is aqueous isopropanol, in a ratio acid:solvent of 1 to 20, with an average water content of 3%. In these experimental conditions the salification, for example, of the R(-) 2-(3-benzoylphenyl)propionic acid with L-lysine gives crystalline solids which are easily filtered and which, after drying, allow to isolate single crystalline individuals of high purity and stability, which may be characterized by I.R. spectrometry and by diffraction of the powder by X-ray.

The salts of the enantiomers of the S(+) and R(-) 2-(3-benzoylphenyl)propionic acids of the present invention, are stable solids, easily filtered and obtainable during the phase of production or purification. They can be in the form of amorphous solids only apparently crystalline, such as the salts of S(+) ketoprofen with L-arginine and of R(-) ketoprofen with D-lysine, or in the form of a crystalline monohydrate such as the salt of S(+) ketoprofen with D-lysine.

The salt of R(-) ketoprofen with L-lysine is one with a residual humidity of about 1%, which in time does not absorb hydration water, and it keeps itself stable in time and is, therefore, particularly manageable, either as such, or as a pharmaceutical composition in which it is contained.

The enantiomeric forms R(-) and S(+) of the 2-(3-benzoylphenyl)propionic acid, or R(-) and S(+) ketoprofen, of convenient optical purity are obtained by optical resolution of the S,R(±) ketoprofen.

In particular, R(-) ketoprofen is preferably obtained through a process which utilizes the salification of (R,S) ketoprofen, at room temperature, with (S) 3-(4-phenylpiperazin-1-yl)propan-1,2-diol in acetone at relatively high dilutions (acid:solvent=1:15). After the filtration of a salt, enantiomerically rich in S(+) ketoprofen and cooling the mother waters to 0°C, the R(-) ketoprofen S(-) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol salt crystallizes, having a highly satisfactory optical purity. As an alternative, the salification at 40°C, in methanol (acid:solvent = 1 g:5 ml) with R(+) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol produces crystallization on cooling of the salt R(-) ketoprofen with R(+) 3-(4-phenylpiperain-1-yl)propane-1,2-diol having an optical purity of about 80%. The desired 98% optical purity is reached by recrystallization from acetone or by successive treatment with S(-) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol in acetone (solute:solvent = 1:10).

S(+) 2-(3-benzoylphenyl)propionic acid having enantiomeric purity (o.p.) of no less than 90% is obtained, at first time, by salifying the racemate S,R(±) 2-(3-benzoylphenyl)propionic

acid in acetone with R(-) 3-(4-phenylpiperazin-1-yl)propane)-1,2-diol. A diastereoisomer salt crystallizes which, after filtration and drying in vacuo, is suspended in water. After acidification of the suspension and extraction with an organic solvent such as, for example, ethyl ether, cyclohexane and/or mixtures thereof, the S(+) 3-(2-benzoylphenyl)propionic acid is obtained with a yield of 60 ± 5%, having an optical purity of at least 90%.

A further improvement in enantiomer yield is coming by a resolution process that uses salification of the racemic acid with half molecular equivalent of the resolvent (S) or (R)-dropropizine.

In comparison to the known salts in which 2-(3-benzoylphenyl)propionic acid is contained in racemic form, the salts of the present invention show a higher purity degree and a greater stability which positively reflects on the handling of the product as such or as a pharmaceutical preparation containing it. In particular, in the case where the salts are formed with the D- and L-lysine enantiomers, the presence of a certain quantity of crystallization water or humidity allows a higher stability of the products.

Moreover the salts of the invention offer the advantage of allowing the preparation of pharmaceutical compositions, the active principle of which is constituted by diastereoisomerically pure single molecular individualities that, as such, give an absolute consistency of quality even with the changing of the preparation batch.

The salts of the invention may be suitably mixed with pharmaceutically acceptable excipients and formulated in a suitable manner for oral, intranasal, parenteral, topical and

inhalant administration. The pharmaceutical compositions, which contain as active principle an effective quantity of one or more salts of the enantiomer S(+) or R(-) 2-(3-benzoylphenyl) propionic acid with an organic achiral base such as tromethamine and/or an organic chiral base selected among L-lysine, D-lysine, L-arginine (S) and (R) 3-(4-phenylpiperazin-1-yl)propane-2,3-diol may be in the form of pills, tablets, dragées, granulates, powders, emulsions, solutions, foams, creams, suppositories and spray.

The quantity of the active principle evaluated as salifying acid which is daily administered may vary depending on the type of the administration chosen, on the age and on the condition of the patient.

In the case of oral administration it varies from 20 to 200 mg which may be divided in several doses or as a long-lasting single dose and, in the case of injectable administration, it varies from 10 to 100 mg which may be divided in several doses. For topical administration concentrations of 1% to 10% are suitable, while in the case of sublingual administration single doses of 10 to 50 mg up to a daily total dose of 200 mg may be administered. For the aerosol administration single doses of 10 to 100 μg up to a daily total dose of a maximum of 800 μg may be administered.

Pharmaceutical formulations suitable for the administration of the salts of the invention as nasal spray in concentration of from 0,1 to 2% and those suitable as colluttory in concentration of from 5 to 15%.

1. Preparation of R(-) 2-(3-benzoylphenyl)propionic acid

To a solution of 400 g (R,S)-2-(3-benzoylphenyl)propionic acid in 8 l acetone are added, under stirring and maintaining the

temperature at 20-25°C by means of external cooling, 440 g S(-) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol. Stirring is maintained for a further 15 minutes until complete dissolution then the salt is allowed to crystallize. After 6 hours the precipitate is filtered, dried in the air and 370 g (2S,2'S') 3'-(4'-phenylpiperazin-1-yl)propane-1',2'-diol 2-(3-benzoyl-phenyl)propionate are obtained.

$[\alpha]_D$ = -2.8° (MeOH, o.p.(S) 82%)

The mother waters are concentrated to a volume of 6 l and cooled to 0°C and separate 280 g (2R,2'S) 3'-(4'-phenylpiperazin-1'-yl)propane-1',2'-diol 2-(3-benzoylphenyl)-propionate.

$[\alpha]_D$ = -19.8° (MeOH, o.p. (R) 97.98%)

Recrystallization from acetone of the compound (solute:solvent 1:10) gives the enantiomerically pure salt, melting at 107-109°C.

$[\alpha]_D$ = -20.8° (MeOH)

A suspension of 25 g (2R,2'S) 3'-(4'-phenylpiperazin-1'-yl)propane-1',2'-diol 2-(3-benzoylphenyl)-propionate in 30 ml water is acidified to pH 1 with 2N sulphuric acid, then twice extracted with 4 ml ethylacetate. The organic phases are collected together, washed with water, made anhydrous on sodium sulphate and evaporated to dryness. By recrystallization of the residue from cyclohexane 11 g R(-) 2-(3-benzoylphenyl)propionic acid, melting at 75-76°C are obtained.

$[\alpha]_D$ = -51° (1% in CH_2Cl_2)

2. Preparation of S(+) 2-(3-benzoylphenyl)propionic acid

Grams 22 of (R,S) 2-(3-benzoylphenyl)propionic acid are treated with 20 g of R(+) 3-(4-phenylpiperazin-1-yl)propane-

1,2-diol in 0.1 l methanol and 18 g of (2R,2'R) 3'-(4'-phenylpiperazin-1'-yl)propane-1',2'-diol 2-(3-benzoylphenyl)-propionate are obtained.

$[\alpha]_D$ = +2.9° (MeOH, o.p. (R) 80%).

Removing by distillation the solvent and crystallizing the residue from 250 ml acetone, 10 g of (2S,2'R) 3'-(4'-phenyl-piperazin-1'-yl)propane-1',2'-diol 2-(3-benzoylphenyl)-propionate, are obtained.

$[\alpha]_D$ = +20° (MeOH, o.p. (S) 98%).

The product is dissolved in water and acidified to give S(+) 2-(3-benzoylphenyl)propionic acid melting at 74-77°C.

$[\alpha]_D$ = +51.2° (1% CH_2Cl_2)

Hereunder are some Examples for a better illustration of the invention.

Example 1

R(-) 2-(3-benzoylphenyl)propionic acid L-lysine salt

R(-) 2-(3-benzoylphenyl)propionic acid D-lysine salt

Grams 300 of R(-) 2-(3-benzoylphenyl)propionic acid are dissolved at room temperature in 3 l of isopropanol.

The solution is heated, under stirring, to 60°C and a solution of 168 g L-lysine in 160 ml of deionized water are added thereto. The solution is filtered hot, diluted, under stirring, with 3 l of isopropanol and left to cool. When the crystallization begins at 48-50°C the stirring is interrupted.

Two hours later a crystalline precipitate is filtered, washed with 600 ml isopropanol. It is dried in the air; after sieving on a 500 μ sieve it is dried in vacuo at 50°C (20 mm Hg). Grams 390 of R(-) 2-(3-benzoylphenyl)propionic acid L-lysine salt, melting at 106-108°C are obtained. The X-ray diffraction spectrum is given in Figure 1, are obtained.

(H_2O)K.F.: 1.4%

$[\alpha]_D$ = +10.6° (c=1%, MeOH); $[\alpha]_{436}$ = +30.4° (c=1% MeOH)

Operating in a similar manner, salifying with D-lysine R(-) 2-(3-benzoylphenyl)propionic acid D-lysine salt melting at 106-108°C, as amorphous solid was obtained.

$[\alpha]_D$ = +1.2° (c=1%, MeOH); $[\alpha]_{436}$ = +10.4° (c=1% MeOH)

Example 2

R(-) 2-(3-benzoylphenyl)propionic acid tris-hydroxymethyl-methylammonium salt

S(+) 2-(3-benzoylphenyl)propionic acid tris-hydroxymethyl-methylammonium salt

A solution of 5 g R(-) 2-(3-benzoylphenyl)propionic acid in isopropanol is treated with a solution of 2.4 g of tris-hydroxymethylaminomethane in 2.5 ml deionized water. It is evaporated with great care under vacuo and the oily residue taken up with 20 ml of ethylether. The crystalline solid which is separated is filtered and it gives 5.4 g of R(-) 2-(3-benzoylphenyl)propionic acid tris-hydroxymethylmethyl-ammonium salt, melting at 101-103°C.

(H_2O)K.F.: 2.05%

$[\alpha]_D$ = +4° (c=1%, MeOH); $[\alpha]_{436}$ = +18.2° (c=1% MeOH)

Operating in a similar manner, by salifying the S(+) 2-(3-benzoylphenyl)propionic acid the S(+) 2-(3-benzoylphenyl)-propionic acid tris-hydroxymethylmethylammonium salt, melting at 102-103°C is obtained.

$[\alpha]_D$ = -4.1° (c=1%, MeOH); $[\alpha]_{436}$ = -17.4° (c=1% MeOH)

Example 3

R(-) 2-(3-benzoylphenyl)propionic acid S(-) 3-(4-phenyl-piperazin-1-yl)propane-1,2-diol salt

R(-) 2-(3-benzoylphenyl)propionic acid R(+) 3-(4-phenyl-

piperazin-1-yl)propane-1,2-diol salt

By salification of a solution of 1 g of R(-) 2-(3-benzoylphenyl)propionic acid in 10 ml acetone heated to 40°C with S(-) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol and followed by cooling at room temperature a precipitate is separated which is filtered and dried in vacuo at 50°C (20 mm Hg) and gives R(-) 2-(3-benzoylphenyl)propionic S(-) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol salt melting at 107-109°C.

$[\alpha]_D$ = -20.4° (c=1%, MeOH); $[\alpha]_{436}$ = -39.5° (c=1% MeOH)

Operating in a similar manner, by salifying with R(+) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol, the R(-) 2-(3-benzoylphenyl)propionic acid R(+) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol salt melting at 118-120°C is obtained.

$[\alpha]_D$ = -1.5° (c=1%, MeOH); $[\alpha]_{436}$ = -3° (c=1% MeOH)

Example 4

R(-) 2-(3-benzoylphenyl)propionic acid L-arginine salt

S(+) 2-(3-benzoylphenyl)propionic acid L-arginine salt

A solution of 0.6 g L-arginine in 1 ml boiling water under gentle stirring is added to a solution of 1.02 g of R(-) 2-(3-benzoylphenyl)propionic acid in 10 ml acetone, heated to 40-45°C; a solid is separated which is filtered hot gives 1.3 g of R(-) 2-(3-benzoylphenyl)propionic acid L-arginine salt melting at 75°C.

$[\alpha]_D$ = +7.7° (c=1%, MeOH); $[\alpha]_{436}$ = -21.3° (c=1% MeOH)

Operating in the same manner, when using the S(+) 2-(3-benzoylphenyl)propionic acid on cooling it separates an oily mass. After separation of the liquid phase, the oily residue is diluted with about 10 ml ethylether, the mass solidifies and is finally dispersed.

The following filtration of the solid gives 1.12 g of S(+) 2-(3-benzoylphenyl)propionic acid L-arginine salt, melting at 85°C.

$[\alpha]_D$ = +1.6° (c=1%, MeOH); $[\alpha]_{436}$ = -3.7° (c=1% MeOH)

Example 5

S(+) 2-(3-benzoylphenyl)propionic acid L-lysine salt .1/4 H_2O

Grams 0.28 of L-lysine dissolved at 80°C in 0.3 ml of distilled water are added to a solution of 0.5 g S(+) 2-(3-benzoylphenyl)propionic acid (o.p. ≥ 90%; $[\alpha]_D$ = + 50° in dichloromethane) in 10 ml isopropil alcohol, heated at 40°C. The so obtained solution is left under stirring; for cooling, an oil is separated which, while it solidifies, is dispersed under stirring, forming a fine crystalline powder. The precipitate is filtered, first washed with isopropyl alcohol and then with ethyl alcohol.

Grams 0.55 g of L-lysine salt of S(+) 2-(3-benzoylphenyl) propionic acid .1/4 H_2O (o.p.of the acid > 99%) is obtained, melting at 147-149°C, the X-ray diffraction spectrum of which is shown in Fig.2.

(H_2O)K.F.: 1% + 0.3%

$[\alpha]_D$ = -0.3° (c=1%, MeOH); $[\alpha]_{436}$ = -9.1° (c=1% MeOH)

Example 6

S(+) 2-(3-benzoylphenyl)propionic acid D-lysine salt .H_2O

Grams 0.32 of D-lysine monohydrate dissolved at 80°C in 0.3 ml of distilled water are added under stirring to a solution of 0.5 g of S(+) 2-(3-benzoylphenyl)propionic acid (o.p. ≥ 90%; $[\alpha]_D$ = + 50° in dichloromethane) in 5 ml absolute ethyl alcohol. It is diluted with 5 ml of absolute ethyl alcohol under continuous stirring and kept at 0°C for 5 hours. The precipitate which is formed is filtered and washed with

absolute ethyl alcohol. After drying 0.5 g of D-lysine salt monohydrate of S(+) 2-(3-benzoylphenyl)propionic acid (o.p > 99%) is obtained, melting at 108-110°C, the x-ray diffraction spectrum of which is shown in Fig.3.

(H_2O)K.F.: 4% + 0.5%

$[\alpha]_D$ = -10.1° (c=1%, MeOH); $[\alpha]_{436}$ = -29.1° (c=1% MeOH)

Example 7

S(+) 2-(3-benzoylphenyl)propionic acid (+) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol salt

Grams 0.5 of (+) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol are added under stirring to a solution of 0.55 g of S(+) 2-(3-benzoylphenyl)propionic acid (o.p. > 90%; $[\alpha]_D$ = + 50° in dichloromethane) in 5 ml of acetone, heated at about 40°C. It is left to cool at room temperature to facilitate a slow separation of the salt. After 3 hours a crystalline precipitate consisting of 3-(4-phenylpiperazin-1-yl)propane-1,2-diol salt of the S(+) 2-(3-benzoylphenyl) propionic acid (o.p. > 99%) and melting at 107-109°C, is separated by filtration.

$[\alpha]_D$ = +20°, 4; $[\alpha]_{436}$ = +38°, 0 (c=1% MeOH)

Example 8

S(+) 2-(3-benzoylphenyl)propionic acid of (-) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol salt

Grams 5 of (-) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol are added under stirring to a solution of 0.55 g of S(+) 2-(3-benzoylphenyl)propionic acid (o.p. > 90%; $[\alpha]_D$ = + 50° in dichloromethane) in 5 ml of acetone, heated at about 40°C. It is left to cool at room temperature to facilitate a slow separation of the salt. After 3 hours a crystalline precipitate consisting of 0.67 g of (-)

3-(4-phenylpiperazin-1-yl)propane-1,2-diol salt of the S(+) 2-(3-benzoylphenyl) propionic acid (o.p. > 99%) and melting at 118-120°C, is separated by filtration.

$[\alpha]_D$ = +1.2 (c=1% MeOH); $[\alpha]_{436}$ = +2.3 (c=1% MeOH)

The crystallographic analysis of the tested compounds has been carried out using a PW1 700 Automated Power Diffratometer System apparatus.

Example 9

By re-crystallization from acetone of each of the enantiomerically rich salts obtained according to preparations 1 and 2 the following diastereoisomerically pure salts are obtained:

- (2S,2'S) 3'-(4'phenylpiperazin-1'-yl)propane-1',2'-diol 2-(3-benzoylphenyl)propionate, melting at 118-120°C $[\alpha]_D$ = +1.2° (MeOH);
- (2R,2'R) 3'-(4'phenylpiperazin-1'-yl)propane-1',2'-diol 2-(3-benzoylphenyl)propionate, melting at 118-120°C $[\alpha]_D$ = +1.5° (MeOH);
- (2R,2'S) 3'-(4'phenylpiperazin-1'-yl)propane-1',2'-diol 2-(3-benzoylphenyl)propionate, melting at 107-109°C $[\alpha]_D$ = +20.4° (MeOH);
- (2S,2'R) 3'-(4'phenylpiperazin-1'-yl)propane-1',2'-diol 2-(3-benzoylphenyl)propionate, melting at 107-109°C $[\alpha]_D$ = +20.4° (MeOH).

CLAIMS

1. A salt of an enantiomer selected from S(+) and R(-) 2-(3-benzoylphenyl)propionic acid with an organic base selected from the group consisting of tris-(hydroxymethyl)aminomethane, L-lysine, D-lysine, L-arginine, (S) 3-(4-phenylpiperazin-1-yl)propane- 1,2-diol and (R) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol.

2. S(+) 2-(3-benzoylphenyl)propionic acid L-lysine salt .1/4 H_2O having the diffraction characteristics which are listed as follows:

Peak n°	D space (ang.)	I/Imax (%)
1	12.7720	12.21
2	10.7535	7.98
3	10.0828	4.33
4	8.5129	14.38
5	7.4181	92.70
6	7.0794	6.39
7	6.6192	25.19
8	6.3171	29.46
9	6.1648	37.62
10	5.9455	54.18
11	5.7515	78.94
12	5.7247	71.21
13	5.3841	50.94
14	5.2264	15.82
15	5.0498	59.79
16	4.4683	100.00
17	4.4133	98.52
18	4.3313	32.35
19	4.2638	32.35
20	4.1649	27.87
21	4.1395	20.57
22	3.9880	86.37
23	3.8241	22.29
24	3.7250	18.60
25	3.6567	32.77
26	3.6302	33.20

Peak n°	D space (ang.)	I/Imax (%)
27	3.5272	39.47
28	3.4374	19.90
29	3.3052	19.90
30	3.1667	25.19
31	3.1134	19.24
32	2.9534	11.95
33	2.8460	4.65
34	2.7126	6.58
35	2.6011	7.16
36	2.4886	3.74
37	2.3855	5.31
38	2.3146	3.88
39	2.1364	2.32
40	1.9261	1.42

3. S(+) 2-(3-benzoylphenyl)propionic acid D-lysine salt monohydrate having the diffraction characteristics given as follows:

Peak n°	D space (ang.)	I/Imax (%)
1	9.7956	19.60
2	9.1056	15.88
3	8.2476	62.67
4	7.1854	11.46
5	6.5400	38.74
6	5.8402	9.77
7	5.3874	25.00
8	5.2549	20.77
9	4.9926	53.17
10	4.9096	100.00
11	4.7367	63.92
12	4.6074	61.04
13	4.4440	32.53
14	4.4155	31.93
15	4.3266	64.33
16	4.1829	26.05
17	4.1172	29.91
18	4.0300	28.78
19	3.8120	48.71

Peak n°	D space (ang.)	I/Imax (%)
20	3.6582	24.74
21	3.4670	11.11
22	3.2828	22.71
23	3.2208	11.29
24	3.1389	12.18
25	3.0527	13.29
26	2.8978	8.06
27	2.7561	9.60
28	2.5991	8.66
29	2.5130	4.56
30	2.3760	4.67
31	2.3255	0.69
32	2.1000	3.92
33	2.0117	1.76
34	1.9626	1.56
35	1.8935	1.70

4. S(+) 2-(3-benzoylphenyl)propionic acid (-) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol salt.

5. S(+) 2-(3-benzoylphenyl)propionic acid (+) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol salt.

6. R(-) 2-(3-benzoylphenyl)propionic acid L-Lysine salt having the diffraction characteristics which are listed as follows:

Peak n°	D space (ang.)	I/Imax (%)
1	15.4982	3.86
2	10.1668	18.84
3	9.3855	15.21
4	8.4662	53.32
5	7.3704	8.26
6	6.7028	32.37
7	6.0016	5.92
8	5.4910	20.40
9	5.3454	18.33
10	4.9982	100.00
11	4.8060	57.24
12	4.6883	58.14

Peak n°	D space (ang.)	I/Imax (%)
13	4.3906	60.85
14	4.1883	33.38
15	3.8515	43.92
16	3.7074	26.94
17	3.4962	10.41
18	3.3109	22.02
19	3.1711	12.38
20	3.0818	13.01
21	2.9072	6.81
22	2.7841	7.93
23	2.6173	6.51
24	2.5279	4.84
25	2.3990	5.78
26	2.3419	3.41
27	2.1063	3.10

7. R(-) 2-(3-benzoylphenyl)propionic acid D-lysine salt.

8. R(-) 2-(3-benzoylphenyl)propionic acid tris-hydroxymethyl-methylamonium salt.

9. S(+) 2-(3-benzoylphenyl)propionic acid tris-hydroxymethyl-methylamonium salt.

10. R(-) 2-(3-benzoylphenyl)propionic acid S(-) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol salt.

11. R(-) 2-(3-benzoylphenyl)propionic acid R(+) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol salt.

12. R(-) 2-(3-benzoylphenyl)propionic acid L-arginine salt.

13. S(+) 2-(3-benzoylphenyl)propionic acid L-arginine salt.

14. A process for obtaining pure diastereoisomeric salts of (R) or (S) 2-(3-benzoylphenyl)propionic acid with R or S 4-(3-phenylpiperazin-1-yl)propane-1,2-diol by fractional crystallization of the diastereoisomeric mixtures of salts.

15. A process for the preparation of the salts of claim 1, characterized in that an enantiomeric form selected from R(-) 2-(3-benzoylphenyl)propionic acid and S(+)

2-(3-benzoylphenyl)propionic acid is salified in a suitable solvent with an organic achiral base such as tris-(hydroxymethyl)aminomethane or an organic chiral base selected from the group consisting of L-lysine, D-lysine, L-arginine, (R) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol and (S) 3-(4-phenylpiperazin-1-yl)propane-1,2-diol.

16. A pharmaceutical composition having anti-inflammatory activity, characterized by the fact that it contains as active principle a therapeutically effective quantity of one or more compounds according to the claims 1-5 in admixture with suitable pharmaceutically acceptable eccipients.

17. A pharmaceutical composition having analgesic activity, characterized in that it contains as active principle one or more compounds according to claims 6-13 in admixture with suitable pharmaceutically acceptable excipients.

18. A pharmaceutical composition according to claim 17, characterized in that the active principle is R(-) 2-(3-benzoylphenyl)propionic acid L-lysine salt.

19. A pharmaceutical composition according to claim 16, characterized in that the active principle is S(+) 2-(3-benzoylphenyl)propionic acid L-lysine salt 1/4 H_2O.

FIGURE 1



FIGURE 2



FIGURE 3


x10 3
1.60
1.44
1.28
1.12
0.96
0.80
0.64
0.48
0.32
0.16
5.0
10.0
15.0
20.0
25.0
30.0

INTERNATIONAL SEARCH REPORT

Interr nal Application No
PCT/IT 94/00020

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07C59/84 C07C229/26 C07C279/14 C07D295/08 A61K31/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 C07C C07D A61K C07B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 502 502 (DOMPE' FARMACEUTICI S.P.A.) 9 September 1992 see claim 1 ---	1
A	BE,A,882 889 (DOMPE' FARMACEUTICI S.P.A.) 18 August 1980 see page 3; example 1 see page 16, line 1 - line 4 see claim 1 --- -/--	1,2

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
29 June 1994	- 6. 07. 94
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	Authorized officer Klag, M

Form PCT/ISA/210 (second sheet) (July 1992)

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DE,A,25 08 895 (SPA SOCIETA PRODOTTI ANTIBIOTICI S.P.A.) 18 September 1975 see page 9, line 22 - line 26 see page 10, line 1 - line 5 see page 12; example 2 see page 13; example 5 see page 14; example 9 see page 15; example 14 see claims 1-3,5,8,9	1-3
A	WO,A,92 18455 (ETHYL CORPORATION) 29 October 1992 see claim 1	1
A	DE,A,41 26 859 (BAYER AG) 18 February 1993 see claims 1-4	1

INTERNATIONAL SEARCH REPORT

formation on patent family members

Inter al Application No
PCT/IT 94/00020

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0502502	09-09-92	JP-A-	5078241	30-03-93
BE-A-882889	18-08-80	NONE		
DE-A-2508895	18-09-75	GB-A-	1497044	05-01-78
		AU-A-	7880375	09-09-76
		BE-A-	826446	30-06-75
		CA-A-	1070324	22-01-80
		FR-A,B	2262975	03-10-75
		JP-C-	1239537	13-11-84
		JP-A-	50126818	06-10-75
		JP-B-	59012650	24-03-84
		NL-A-	7502644	09-09-75
		US-A-	4279926	21-07-81
WO-A-9218455	29-10-92	US-A-	5162576	10-11-92
DE-A-4126859	18-02-93	EP-A-	0531700	17-03-93